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Atrial ﬁbrillation (AF) is the most common
arrhythmia in clinical practice and the occurrence
of AF increases with age.1,2) The morbidity and
mortality associated with AF are relatively high
and AF adversely aﬀects the quality of life. There-
fore, treatment of AF is very important in clinical
settings. Non-pharmacological treatment of AF
with catheter-based pulmonary vein ablation or
isolation has considerably progressed and it may
be successfully used in younger and symptomatic
patients with refractory paroxysmal AF.3) In addi-
tion, introduction of novel anticoagulants such as
dabigatran4) may have a great impact on the
treatment of AF. Many large-scale clinical trials
comparing rate control with rhythm control have not
yet indicated that rhythm control is any better than
rate control in decreasing morbidity and mortality
rate of AF patients.5) One possible explanation for
the ineﬀectiveness of rhythm control is that proar-
rhythmic risk and toxic eﬀects associated with
currently available antiarrhythmic drugs adversely
aﬀect outcomes. Antiarrhythmic drugs currently
used for AF treatment sometimes prolong QT
interval and produce conduction disturbance. Many
eﬀorts have been made to discover an ideal
antiarrhythmic drug that can eﬀectively and safely
terminate AF and prevent AF recurrence. One of
ideal candidates may be an antiarrhythmic drug with
selective aﬃnity for the ion channels that are
speciﬁcally involved in atrial repolarization. Anoth-
er candidate may be an antiarrhythmic drug with
multichannel blocking action, which can provide
successful rhythm control in a similar fashion with
amiodarone. Here I brieﬂy mention several anti-
arrhythmic drugs targeting multiple cardiac ion
channels or having a speciﬁc aﬃnity to the atrial-
speciﬁc ion channels, which are now under clinical
investigation.
Many ionic currents are known to contribute to
atrial action potential. For the upstroke of atrial
action potential the fast Naþ current (INa) ﬂows
inwardly in a way similar to that in ventricular action
potential. The L-type Ca2þ current (ICa) contributes
to the maintenance of plateau phase of atrial action
potential. Several Kþ currents such as the transient
outward current (Ito), the ultra-rapid delayed rectiﬁer
Kþ current (IKur), rapid (IKr) and slow components
(IKs) of the delayed rectiﬁer K
þ current, the acetyl-
choline-receptor operated Kþ current (IK.ACh) and
the inward rectiﬁer Kþ current (IK1) contribute to the
repolarization of atrial action potential (Figure 1).
Among these Kþ currents, IKur and IK.ACh are
assumed to be Kþ currents speciﬁcally involved in
the repolarization processes in atrial cells. An
attractive prospect in antiarrhythmic drug therapy
for AF may be the innovative development of agents
with highly selective aﬃnity to the ion channels
through which atria-speciﬁc Kþ currents ﬂow.
Dronedarone is a multichannel blocker having a
chemical structure similar to amiodarone. The drug
acutely inhibits INa, ICa and IKr,
6) as shown in
Figure 1. The drug also potently inhibits the atria-
speciﬁc Kþ current IK.ACh.7) A large-scale clinical
trial indicated that dronedarone signiﬁcantly reduced
the incidence of hospitalization due to cardiovascu-
lar events or death in patients with AF as compared
to placebo.8) However, it has been reported that the
drug may increase early mortality in patients with
severe heart failure and left ventricular systolic
dysfunction.9)
Main target of vernakalant (RSD1235) is atria-
speciﬁc Kv1.5 channel through which IKur ﬂows. The
drug inhibits not only IKur, but also Ito, IKr and INa in
similar concentrations10) (Figure 1). It was reported
that the new atrial-selective antiarrhythmic drug
was eﬃcacious and safe for converting recent onset
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AF to sinus rhythm after intravenous administra-
tion.11) Taking the electropharmacological eﬀects
into consideration, however, we would have to be
careful in monitoring prolongation of QT interval
and QRS complex in ECG after administration of
vernakalant.
More recently a highly selective acetylcholine-
receptor operated Kþ channel blocker, NTC-801, has
been developed as an atrial-selective antiarrhythmic
drug in Japan.12) The drug selectively inhibits IK.ACh
and does not aﬀect other ionic currents such as INa,
ICa, IKr, IKs, Ito or IK1 (Figure 1). The drug has been
shown to convert AF to sinus rhythm in various AF
models of experimental animals.12) Paroxysmal AF
occurring at night, at rest, and/or after meals or
alcohol may be triggered at least partly by activation
of IK.ACh. Atrial cells from patients with chronic AF
are reported to show constitutively active KACh
channel current.13) It has been reported that NTC-
801 can decrease AF inducibility in an AF model
with electrical remodeling. Therefore, NTC-801 may
become a unique anti-AF drug without electrophy-
siological side eﬀects in the ventricle.
Several oral anticoagulants with novel mecha-
nisms have been developed and are being clinically
available in the near future. Therefore, rate control
strategy will become the ﬁrst choice for the treat-
ment of AF, especially persistent AF. However, if an
eﬀective atrial-selective antiarrhythmic drug without
serious side eﬀects is developed, rhythm control may
become another choice of AF therapy.
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Figure 1 Eﬀects of novel antiarrhythmic drugs, dronedarone, vernakalant and NTC-801, on ionic currents involved in atrial
action potential.
Ionic currents indicated by shaded circle are assumed to be atria-speciﬁc.
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